Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Miller, J. S., Soignier, Y., Panoskaltsis‐Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D. H., Le, C. T., DeFor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,894

Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies

Mangal, J. L., Handlos, J. L., Esrafili, A., Inamdar, S., Mcmillian, S., Wankhede, M., Gottardi, R., & Acharya, A. P. (2021) · Cancers · doi:10.3390/cancers13051123 · Cited by 26

Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy

Apollonio, B., Ioannou, N., Papazoglou, D., & Ramsay, A. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626818 · Cited by 27

Reliance on Cox10 and oxidative metabolism for antigen-specific NK cell expansion

Mah-Som, A. Y., Keppel, M. P., Tobin, J. M., Kolicheski, A., Saucier, N., Sexl, V., French, A. R., Wagner, J. A., Fehniger, T. A., & Cooper, M. A. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109209 · Cited by 27

Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner

Etxebeste-Mitxeltorena, M., del Rincón-Loza, I., & Martín-Antonio, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717850 · Cited by 26

Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy

Wan, X., Song, M., Wang, A., Zhao, Y., Wei, Z., & Lu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.747914 · Cited by 27

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies

Krug, A., Martinez-Turtos, A., & Verhoeyen, E. (2021) · Cancers · doi:10.3390/cancers14010183 · Cited by 28

Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering

Ye, Y., Yang, L., Yuan, X., Huang, H., & Luo, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.790299 · Cited by 29

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

Thanarajasingam, G., Minasian, L. M., Bhatnagar, V., Cavalli, F., Claro, R. A. D., Dueck, A. C., El-Galaly, T. C., Everest, N., Geißler, J., Gisselbrecht, C., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00045-x · Cited by 27

2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy

Peng, Y., Fu, S., & Zhao, Q. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0422-506r · Cited by 25

CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia

Zheng, N.-S., Zhao, X.-Y., Wei, D., Miao, J., Liu, Z.-K., Yong, Y., Zhang, R., Guo, Y., He, L., Wang, B., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215762 · Cited by 28

Tumor immunotherapy: Mechanisms and clinical applications

Nong, C., Guan, P., Li, L., Zhang, H., & Hu, H. (2022) · MedComm – Oncology · doi:10.1002/mog2.8 · Cited by 27

Nanobiomaterials to modulate natural killer cell responses for effective cancer immunotherapy

Raza, A., Rossi, G. R., Janjua, T. I., Souza-Fonseca-Guimarães, F., & Popat, A. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.06.011 · Cited by 26

Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic

Fenton, G. A., & Mitchell, D. A. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2257 · Cited by 26

Mapping the interplay between NK cells and HIV: therapeutic implications

Anderko, R. R., & Mailliard, R. B. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiac007 · Cited by 28

Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy

Xia, W., Chen, J., Hou, W., Chen, J., Xiong, Y., Li, H., Qi, X., Xu, H. Y., Xie, Z., Li, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076843 · Cited by 27

Reprogramming natural killer cells for cancer therapy

Wang, K., Wang, L., Wang, Y., Xiao, L., Wei, J., Hu, Y., Wang, D., & Huang, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.027 · Cited by 28

Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma

Braun, A., Gouni, S., Pulles, A. E., Strati, P., Minnema, M. C., & Budde, L. E. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_433516 · Cited by 26

Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins

Wang, X., Cabrera, F. G., Sharp, K. L., Spencer, D. M., Foster, A. E., & Bayle, J. H. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.019 · Cited by 29

Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies

Melero, I., Ochoa, M. C., Molina, C., Sánchez‐Gregorio, S., Garasa, S., Luri‐Rey, C., Hervás‐Stubbs, S., Casares, N., Elizalde, E., Gomis, G., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202317804 · Cited by 26

The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation

Hadjis, A. D., & McCurdy, S. R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1358668 · Cited by 26

Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti‐tumour activity

Wang, Y., Li, J., Wang, Z., Liu, Y., Wang, T., Zhang, M., Xia, C., Zhang, F., Huang, D., Zhang, L., et al. (2024) · Cell Proliferation · doi:10.1111/cpr.13683 · Cited by 27

Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells

Park, D. H., Bhojnagarwala, P. S., Liaw, K., Bordoloi, D., Tursi, N. J., Zhao, S., Binder, Z. A., O’Rourke, D. M., & Weiner, D. B. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009604 · Cited by 25

The current socioeconomic and regulatory landscape of immune effector cell therapies

Sainatham, C., Yadav, D., Babu, A. D., Tallapalli, J. R., Kanagala, S. G., Filippov, E., Murillo-Chavez, F., Ahmed, N., & Lutfi, F. U. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1462307 · Cited by 30

Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy

Dehghan, F., Metanat, Y., Askarizadeh, M., Ahmadi, E., & Moradi, V. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1511931 · Cited by 26

A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells

Yi, E., Lee, E., Park, H. J., Lee, H. H., Yun, S., & Kim, H. S. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03351-5 · Cited by 30

DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity

Li, Y., Wang, J., Zhou, L., Gu, W., Qin, L., Peng, D., Li, S., Zheng, D., Wu, Q., Long, Y., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adm8251 · Cited by 27

Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8+ T cell activation in patients with advanced colorectal cancer

Li, B., Zhu, X., Ge, J., Zhang, H., Gao, Y., Bao, X., Dai, X., Du, Z., Tu, X., Zhou, T., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.026 · Cited by 26

Beyond CAR-T: Engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy

Zhang, F., Samarkhazan, H. S., Pooraskari, Z., & Bayani, A. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104912 · Cited by 26

The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection

Rajaram, S., Canaday, L. M., Ochayon, D. E., Rangel, K., Ali, A., Gyurova, I. E., Krishnamurthy, D., Fletcher, J. S., Reighard, S. D., Cox, A., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.018 · Cited by 25

Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies

Sakemura, R. L., Cox, M. J., Hefazi, M., Siegler, E. L., & Kenderian, S. S. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1894648 · Cited by 25

Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential

Maes, K., Mondino, A., Lasarte, J. J., Agirre, X., Vanderkerken, K., Prósper, F., & Breckpot, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652160 · Cited by 25

Cell therapy strategies for COVID-19: Current approaches and potential applications

Zaki, M. M., Lesha, E., Said, K., Kiaee, K., Robinson‐McCarthy, L. R., George, H., Hanna, A., Appleton, E., Liu, S., Ng, A. H. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg5995 · Cited by 25

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

Chung, H., Jung, H., & Noh, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212126 · Cited by 28

Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies

Mazza, R., & Maher, J. F. (2021) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-021-00640-7 · Cited by 26

Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia

Maucher, M., Srour, M., Danhof, S., Einsele, H., Hudecek, M., & Yakoub‐Agha, I. (2021) · Cancers · doi:10.3390/cancers13246157 · Cited by 25

gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials

Takeda, K., Morita, S., & Taguri, M. (2022) · Biometrical Journal · doi:10.1002/bimj.202100263 · Cited by 25

Umbilical cord blood: an undervalued and underutilized resource in allogeneic hematopoietic stem cell transplant and novel cell therapy applications

Shi, P. A., Luchsinger, L. L., Greally, J. M., & Delaney, C. S. (2022) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000732 · Cited by 27

The role of CCL2, CCL7, ICAM-1, and VCAM-1 in interaction of endothelial cells and natural killer cells

Jun, H. W., Lee, H. K., Na, I. H., Lee, S. J., Kim, K., Park, G., Kim, H. S., Son, D. J., Kim, Y., Hong, J. T., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109332 · Cited by 25

Pediatric Acute Lymphoblastic Leukemia Emerging Therapies—From Pathway to Target

Ivanov, A. V., Alecsa, M., Popescu, R. M., Stârcea, I. M., Mocanu, A., Rusu, C., & Miron, I. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054661 · Cited by 28

Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments

Li, X., Li, W., Xu, L., & Song, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002818 · Cited by 26

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?

Karschnia, P., Blobner, J., Teske, N., Schöberl, F., Fitzinger, E., Dreyling, M. H., Tonn, J., Thon, N., Subklewe, M. S., & von Baumgarten, L. (2021) · Cancers · doi:10.3390/cancers13102503 · Cited by 25

Cytokine-induced killer cells: new insights for therapy of hematologic malignancies

Sevari, F. G., Mehdizadeh, A., Abbasi, K., Hejazian, S. S., & Raeisi, M. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03869-z · Cited by 25

Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy

Fang, M., Allen, A. G., Luo, C., & Finn, J. D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1457629 · Cited by 26

Gastric Cancer Signaling Pathways and Therapeutic Applications

Wu, M., Yuan, S., Liu, K., Wang, C., & Wen, F. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241271935 · Cited by 24

Engineering resilient CAR T cells for immunosuppressive environment

Khalifeh, M., & Salman, H. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.035 · Cited by 25

Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy

Li, F., Chen, Y., Pang, M., Yang, P., & Jing, H. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13592 · Cited by 25

CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma

Stikvoort, A., van der Schans, J., Sarkar, S., Poels, R., Ruiter, R. W. J., Naik, J., Yuan, H., de Bruijn, J. D., van de Donk, N. W. C. J., Zweegman, S., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000596 · Cited by 25

Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials

Sheng‐Kai, K., Lee, C., Liu, K., Wei, J. C., Lee, Y., & Wang, L. (2021) · Pathogens · doi:10.3390/pathogens10121537 · Cited by 24

Natural killer cells and acute myeloid leukemia: promises and challenges

Rahmani, S., Yazdanpanah, N., & Rezaei, N. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03217-1 · Cited by 24

CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells

Dezfouli, A. B., Yazdi, M., Benmebarek, M.-R., Schwab, M., Michaelides, S., Micciché, A., Geerts, D., Stangl, S., Klapproth, S., Wagner, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883694 · Cited by 23

CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges

Khorasani, A. B. S., Yousefi, A., & Bashash, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109041 · Cited by 24

Minimally invasive detection of cancer using metabolic changes in tumor-associated natural killer cells with Oncoimmune probes

Ishwar, D., Haldavnekar, R., Venkatakrishnan, K., & Tan, B. (2022) · Nature Communications · doi:10.1038/s41467-022-32308-x · Cited by 24

Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise?

Damele, L., Spaggiari, G. M., Parodi, M., Mingari, M. C., Vitale, M., & Vitale, C. (2022) · Cancers · doi:10.3390/cancers14184439 · Cited by 26

Metabolic hallmarks of natural killer cells in the tumor microenvironment and implications in cancer immunotherapy

Yang, Y., Chen, L., Zheng, B., & Zhou, S. (2022) · Oncogene · doi:10.1038/s41388-022-02562-w · Cited by 27

CAR NK Cells: The Future Is Now

Raftery, M. J., Franzén, A. S., & Pecher, G. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061521-082320 · Cited by 24

Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications

Mucha, S. R., & Rajendram, P. (2023) · Current Oncology · doi:10.3390/curroncol30050378 · Cited by 26

Programmed Remodeling of the Tumor Milieu to Enhance NK Cell Immunotherapy Combined with Chemotherapy for Pancreatic Cancer

Yang, X., Li, C., Yang, H., Li, T., Ling, S., Zhang, Y., Wu, F., Liu, X., Liu, S., Fan, C., et al. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c00002 · Cited by 24

Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?

Al‐Ani, M., Elemam, N. M., Hundt, J. E., & Maghazachi, A. A. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s269797 · Cited by 24

Targeting NK Cells for HIV-1 Treatment and Reservoir Clearance

Duan, S., & Liu, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842746 · Cited by 23

Boosting CAR-T cell therapy with CRISPR technology

Yan, L., Gao, S., Wang, X., Zhou, X., Limsakul, P., & Wu, Y. (2024) · hLife · doi:10.1016/j.hlife.2024.06.002 · Cited by 24

CAR-NK cell therapy in AML: Current treatment, challenges, and advantage

Bahramloo, M., Shahabi, S. A., Kalarestaghi, H., Rafat, A., Mazloumi, Z., Samimifar, A., & Asl, K. D. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117024 · Cited by 23

The landscape of CAR-engineered innate immune cells for cancer immunotherapy

Tsahouridis, O., Xu, M., Song, F., Savoldo, B., & Dotti, G. (2025) · Nature Cancer · doi:10.1038/s43018-025-01015-z · Cited by 26

Novel approaches to clinical trial design in cancer neuroscience

Jones, G., Anderson, J. L., Nguyen, P. T., Gleber‐Netto, F. O., Hwang, W. L., Puduvalli, V. K., Monje, M., & Amit, M. (2025) · Neuron · doi:10.1016/j.neuron.2025.08.015 · Cited by 24

Dysfunction of natural killer cells promotes immune escape and disease progression in endometriosis

Jiang, W., Xu, W., & Chen, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1657605 · Cited by 23

New power in cancer immunotherapy: the rise of chimeric antigen receptor macrophage (CAR-M)

Jing, J., Chen, Y., Chi, E., Li, S., He, Y., Wang, B., Shen, H., Fan, L., Wang, J., Shangguan, T., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07115-9 · Cited by 25

Natural Killer Cells in Immunotherapy: Are We Nearly There?

Bachiller, M., Battram, A. M., Pérez-Amill, L., & Martín-Antonio, B. (2020) · Cancers · doi:10.3390/cancers12113139 · Cited by 26

Fc γ receptor IIIa/CD16a processing correlates with the expression of glycan-related genes in human natural killer cells

Patel, K., Rodríguez, M. C., Lorenz, W. W., Mace, E. M., & Barb, A. W. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015516 · Cited by 23

Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer

Fix, S. M., Jazaeri, A. A., & Hwu, P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1083 · Cited by 25

Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review

Nishida, H. (2021) · Cancers · doi:10.3390/cancers13112712 · Cited by 23

The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors

Velichinskii, R. A., Streltsova, M. A., Kust, S. A., Sapozhnikov, A. M., & Kovalenko, E. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111385 · Cited by 23

An Inter‐Supplementary Biohybrid System Based on Natural Killer Cells for the Combinational Immunotherapy and Virotherapy of Cancer

Ding, L. J., Gao, Q., Xu, Z., Cai, L., Chen, S., Zhang, X., Cao, P., & Chen, G. (2021) · Advanced Science · doi:10.1002/advs.202103470 · Cited by 23

Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned

Can, İ., Cox, M. J., Siegler, E. L., Sakemura, R. L., & Kenderian, S. S. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.02.001 · Cited by 23

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

Perutelli, F., Jones, R., Griggio, V., Vitale, C., & Coscia, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837531 · Cited by 24

Natural killer cells: the next wave in cancer immunotherapy

Chen, X., Jiang, L., & Liu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954804 · Cited by 28

Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells

Feng, J., Xu, H.-C., Cinquina, A., Wu, Z., Zhang, W., Sun, L., Chen, Q., Tian, L., Song, L., Pinz, K. G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997482 · Cited by 23

Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B

Feigl, F. F., Stahringer, A., Peindl, M., Dandekar, G., Koehl, U., Fricke, S., & Schmiedel, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043129 · Cited by 23

Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer

Iyoda, T., Yamasaki, S., Ueda, S., Shimizu, K., & Fujii, S. (2023) · Biomolecules · doi:10.3390/biom13020348 · Cited by 23

XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression

Fisher, J. G., Doyle, A. D. P., Graham, L. V., Sonar, S., Sale, B., Henderson, I., Rio, L. D., Johnson, P., Landesman, Y., Cragg, M. S., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01984-z · Cited by 23

Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer

Jacobs, M. T., Wong, P., Zhou, A. Y., Becker‐Hapak, M., Marín, N. D., Marsala, L. I., Foster, M., Foltz, J. A., Cubitt, C. C., Tran, J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0156 · Cited by 25

Cytokine‐Induced Memory‐Like NK Cells: Emerging strategy for AML immunotherapy

Bakhtiyaridovvombaygi, M., Yazdanparast, S., Mikanik, F., Izadpanah, A., Parkhideh, S., Ghasabeh, A. S., Roshandel, E., Hajifathali, A., & Gharehbaghian, A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115718 · Cited by 25

Cancer immunotherapy and its facilitation by nanomedicine

Sui, C., Wu, H., Li, X., Wang, Y., Wei, J., Yu, J., & Wu, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00625-6 · Cited by 23

Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies

St‐Pierre, F., Bhatia, S., & Chandra, S. (2021) · Cancers · doi:10.3390/cancers13081988 · Cited by 24

Nanomedicine-Mediated Optimization of Immunotherapeutic Approaches in Cervical Cancer

Venkatas, J., & Singh, M. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0044 · Cited by 25

Innate immunity: Looking beyond T-cells in radiation and immunotherapy combinations

McMahon, R. A., D’Souza, C., Neeson, P. J., & Siva, S. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100940 · Cited by 22

A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma

Demaria, O., Habif, G., Vétizou, M., Gauthier, L., Remark, R., Chiossone, L., Vagne, C., Rebuffet, L., Courtois, R., Denis, C., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adp3720 · Cited by 22

High-risk MCL: recognition and treatment

Jain, P., & Wang, M. L. (2024) · Blood · doi:10.1182/blood.2023022354 · Cited by 23

NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study

Wang, D., Ли, Б., Shen, G., Zhang, H., Gao, Y., Du, Z., Dai, X., Bao, X., Zhu, X., Tong, Z., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04196-9 · Cited by 26

Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E

Fisher, J. G., Walker, C. J., Doyle, A. D. P., Johnson, P., Forconi, F., Cragg, M. S., Landesman, Y., Khakoo, S. I., & Blunt, M. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.785635 · Cited by 23

Multipurposing CARs: Same engine, different vehicles

Hossian, A. K. M. N., Hackett, C. S., Brentjens, R. J., & Rafiq, S. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.012 · Cited by 24

Natural killer cell therapy: A new frontier for obesity-associated cancer

Mylod, E., Lysaght, J., & Conroy, M. J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215620 · Cited by 22

Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer

Ferrer, G., Álvarez‐Errico, D., & Esteller, M. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac088 · Cited by 23

NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives

Mortezaee, K., & Majidpoor, J. (2022) · Medical Oncology · doi:10.1007/s12032-022-01735-7 · Cited by 23

Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health

Presti, E. L., Nuzzo, D., Almahmeed, W. A., Al‐Rasadi, K., Al-Alawi, K., Banach, M., Banerjee, Y., Ceriello, A., Cesur, M., Cosentino, F., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166559 · Cited by 22

Emerging frontiers in immuno- and gene therapy for cancer

Gustafson, M. P., Ligon, J. A., Bersenev, A., McCann, C. D., Shah, N. N., & Hanley, P. J. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.10.002 · Cited by 24

Engineered IL-15/IL-15R α -expressing cellular vesicles promote T cell anti-tumor immunity

Fang, W., Li, L., Lin, Z., Zhang, Y., Jing, Z., Li, Y., Zhang, Z., Hou, L., Liang, X., Zhang, X., et al. (2022) · Extracellular Vesicle · doi:10.1016/j.vesic.2022.100021 · Cited by 22

Contribution of natural killer cells in innate immunity against colorectal cancer

Ghazvinian, Z., Abdolahi, S., Tokhanbigli, S., Tarzemani, S., Piccin, A., Zali, M. R., Verdi, J., & Baghaei, K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1077053 · Cited by 23

Nonviral technologies can pave the way for CAR-NK cell therapy

Bexte, T., Reindl, L. M., & Ullrich, E. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad074 · Cited by 22

Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models

Yang, M., Guan, T., Chen, C., He, L., Wu, H.-M., Zhang, R.-D., Li, Y., Lin, Y.-C., Zeng, H., & Wu, J. (2023) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000483 · Cited by 22

Actin cytoskeleton remodeling at the cancer cell side of the immunological synapse: good, bad, or both?

Ockfen, E., Filali, L., Fernandes, D. P., Hoffmann, C., & Thomas, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1276602 · Cited by 24

Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells

Klaihmon, P., Luanpitpong, S., Kang, X., & Issaragrisil, S. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03153-9 · Cited by 22

Abstract 2907: Development of a CAR-NK cellular platform for cancer immunotherapy

Gregoli, K. D., Mode, R., Mitchell, K., Lopez, D. C., de Munnik, S., McLaughlin, R. J., Moiset, G., Brackenbury, L., Schewitz‐Bowers, L. P., & Nunan, R. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-2907

Safety and Feasibility of a 41BB Co-Stimulated CD19 CAR-NK Cell Therapy in Refractory/Relapsed Large B-Cell Lymphoma

Qian, W., Lei, W., Liu, H., Chen, W., Liang, Y., Sun, Y. E., Tong, X., & Liang, A. (2024) · Blood · doi:10.1182/blood-2024-202988 · Cited by 5

The Efficacy and Safety of CD-19 Directed CAR-NK Therapy in Adults with B-Cell Malignancies: A Meta-Analysis

Carfagnini, C. L., Singh, R., Bechara, S. B., & Kandula, M. (2024) · Blood · doi:10.1182/blood-2024-212016 · Cited by 4

ENHANCED ANTI-TUMOR ACTIVITY OF CD19.CAR-NK CELLS BY INCORPORATING IL-27

Biggi, A., Silvestre, R., Azevedo, J., Tirapelle, M., Malmegrim, K. C. R., Figueiredo, M., Covas, D. T., & Picanço‐Castro, V. (2023) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2023.09.983 · Cited by 1

Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

Lei, W., Liu, H., Deng, W., Chen, W., Liang, Y., Gao, W., Yuan, X., Guo, S., Li, P., Wang, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00940-3 · Cited by 78